Stephen Wayne Gutkin Author of Evaluating Organization Development
FEATURED AUTHOR

Stephen Wayne Gutkin

Director, Scientific Publication Writing
Ascentage Pharma Group

For 30 years, I have enjoyed success as a medical writer, editorial manager, and publication planner. Collaborating with 500 investigators in academia, and two of the top three life sciences companies, from São Paulo to Shanghai, I've contributed 200 papers to peer-reviewed journals. A nearly lifelong grammarian, I reside in northern New Jersey with my beloved wife and son, who generously shared me with my book project and without whom it simply would not have been possible.

Subjects: Biomedical Science

Biography

Stephen W. Gutkin is a medical communications
professional who has 30 years of experience
in medical writing, editing, editorial
management, and publication planning and
execution. A coauthor of 14 papers in peer-reviewed
journals, Mr. Gutkin served as president
of Rete Biomedical Communications Corp. for 23
years, during which the organization consulted
widely with industry and academia.

A summa cum laude graduate of Duke University, he served as arts
critic for the Brooklyn Paper; research scientist for a
toxicology laboratory that also assayed psychiatric
biomarkers; and as copy chief and medical writer
with McGraw-Hill Healthcare (New York).

He has delivered invited lectures on medical writing at
Johnson & Johnson and the Center for Business
Intelligence (now CBINET).

Mr. Gutkin is a member of the American Academy
for the Advancement of Science, American
Medical Writers Association,
International Society for Medical Publication
Professionals, and Phi Beta Kappa.

Stephen resides in Midland Park, NJ, with his
wife, son, and colorful pet menagerie.

Areas of Research / Professional Expertise

    CNS disorders
    Health economics and outcomes research
    Vascular diseases

Personal Interests

    Golf
    Reading
    Travel

Books

Featured Title
 Featured Title - Writing High-Quality Medical Publications - 1st Edition book cover

Articles

Curr Med Res Opin. 2014;30:655-665.

Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: Analysis of a primary-care database.


Published: Feb 27, 2014 by Curr Med Res Opin. 2014;30:655-665.
Authors: Jameson K, Zhang Q, Zhao C, Ramey DR, Tershakovec AM, Gutkin SW, Marrett E.

Less than half of UK high-CVD-risk patients receiving atorvastatin monotherapy achieved guideline-recommended treatment targets for TC, and less than two-thirds of patients with CHD/AVD + DM had values below TC (4.0 mmol/L) or LDL-C (2.0 mmol/L) targets. More effective lipid-lowering strategies may be warranted to optimize cholesterol lowering and target attainment in high-risk patients. Limitations of this study include its retrospective, observational nature.

Child Adolesc Psychiatry Mental Health. 2011;5:14.

Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies.


Published: May 11, 2011 by Child Adolesc Psychiatry Mental Health. 2011;5:14.
Authors: Dickson RA, Maki E, Gibbins C, Gutkin SW, Turgay A, Weiss MD.

Reductions in core ADHD symptoms during atomoxetine treatment are gradual. Although approximately one-half of study participants showed improvement at 1 month of atomoxetine treatment, remission criteria were not met until about 3 months. Understanding the time course of children's responses to atomoxetine treatment may inform clinical decision making and also influence the durations of trials comparing the effects of this medication with other ADHD treatments.

 J Am Acad Nurse Practitioners. 2011;23:320-330.

Optimizing treatment outcomes with phosphodiesterase inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall health.


Published: Jan 27, 2011 by J Am Acad Nurse Practitioners. 2011;23:320-330.
Authors: Sadovsky R, Brock G, Gray M, Jensen PK, Gutkin SW, Sorsaburu S.

Strategies to optimize responses to PDE5 therapy are summarized by the mnemonic “EPOCH.”

J Sex Med 2010;7:203–215.

Sexual satisfaction in men with erectile dysfunction: correlates and potential predictors


Published: May 01, 2010 by J Sex Med 2010;7:203–215.
Authors: Althof SE, Buvat J, Gutkin SW, Belger M, Stothard DR, Fugl-Meyer A

Sexual satisfaction is associated with certain baseline, on‐treatment, and endpoint variables in ED patients. Further studies are needed to confirm these preliminary findings and explore their meaning for female partners.

 Int J Clin Pract. 2009;63:1214-1230.

Toward a new "EPOCH": optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.


Published: Jul 13, 2009 by Int J Clin Pract. 2009;63:1214-1230.
Authors: Sadovsky R, Brock GB, Gutkin SW, et al.

physician activities to promote favourable treatment outcomes may be captured under the mnemonic ‘EPOCH’...

Eur J Endocrinol. 2008;158:773-784.

Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?


Published: Jun 01, 2008 by Eur J Endocrinol. 2008;158:773-784.
Authors: Van Gaal LF, Gutkin SW, Nauck MA.

This article reviews recent clinical trials comparing therapy with the incretin mimetic exenatide to insulin in patients with oral treatment failure, identifies factors consistent with the use of each treatment, and delineates areas for future research.

J Cardiovasc Pharmacol. 2008;51:331-351.

Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.


Published: Jan 01, 2008 by J Cardiovasc Pharmacol. 2008;51:331-351.
Authors: Abdel-Maksoud M, Sazonov V, Gutkin SW, et al.
Subjects: Biomedical Science

Elevated triglycerides constitute a plausible therapeutic target in certain patients with coronary heart disease (and/or insulin resistance) but without profound LDL-C elevations.

Curr Med Res Opinion. 2008;24:249-259.

Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia.


Published: Nov 30, 2007 by Curr Med Res Opinion. 2008;24:249-259.
Authors: Assmann G, Kannenberg F, Ramey DR, Musliner TA, Gutkin SW, Veltri EP.

The observed effects of co-administration of ezetimibe and statins on non-cholesterol sterols are consistent with net inhibition of sterol absorption (driven by ezetimibe) in conjunction with net inhibition of cholesterol synthesis (driven by statins).

Br J Urol International. 2007;99:376-382.

The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners.


Published: Nov 28, 2006 by Br J Urol International. 2007;99:376-382.
Authors: Brock G, Chan J, Carrier S, Chan M, Salgado L, Klein AH, Lang C, Horner R, Gutkin SW, Dickson R.

Patients with ED (and their partners) who changed from sildenafil to tadalafil treatment or vice versa in a routine clinical practice setting had higher treatment satisfaction when taking tadalafil than sildenafil, as assessed by most measures of EDITS.

Curr Med Res Opinion. 2006;22:1065-1073.

Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) Study.


Published: Apr 26, 2006 by Curr Med Res Opinion. 2006;22:1065-1073.
Authors: Jacobson TA, Gutkin SW, Harper CR.

Although a simple global risk educational tool did not improve the targeting of statin therapy to patients at high absolute coronary risk, it may be of benefit in targeting moderate-risk individuals who do not have markedly elevated low-density lipoprotein cholesterol (LDL‐C) levels. Future research should evaluate the effects of physicians performing their own Framingham risk calculations on statin prescribing and on cholesterol goal attainment.

Curr Med Res Opinion. 2005;21:1389-1399.

Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.


Published: Aug 10, 2005 by Curr Med Res Opinion. 2005;21:1389-1399.
Authors: Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin SW, Yin D.

Lipid management strategies in Europe during the study period were dominated by statin monotherapy. Even after prolonged follow-up on lipid-modifying therapy, approximately 60% of Europeans studied did not achieve guideline recommended cholesterol goals.

Cutis. 2001;67:1-15.

Clinical management of psoriasis: principles and practice.


Published: Jan 01, 2001 by Cutis. 2001;67:1-15.
Authors: Lebwohl M, Feldman SR, Walther R, Shelk J, Morgan P, Gutkin SW.

A chronic condition that compromises many patients' quality of life, psoriasis is treatable with a range of agents, either alone or in combination. Clinical management strategies using these therapies can be organized as a stepped-care approach.